Switch to:
More From Other Websites
Alkermes Begins a Study on ALKS7106 for Treatment of Pain Aug 27 2014
Alkermes Gains on Aripiprazole Lauroxil NDA Submission Aug 26 2014
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain Aug 26 2014
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain Aug 26 2014
Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of... Aug 25 2014
Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of... Aug 25 2014
Wall Street Transcript Interview with Howard Zauberman, the President and CEO of Vision-Sciences,... Aug 08 2014
Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up Aug 04 2014
Alkermes plc Reports Second Quarter 2014 Financial Results Jul 31 2014
Q2 2014 Alkermes plc Earnings Release - Before Market Open Jul 31 2014
ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 31 2014
Alkermes plc Reports Second Quarter 2014 Financial Results Jul 31 2014
Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major... Jul 30 2014
Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major... Jul 30 2014
Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Jul 24 2014
Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Jul 24 2014
Alkermes' Pipeline Development Impresses, Key Updates Ahead Jul 21 2014
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple... Jul 17 2014
Alkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS Jul 17 2014


Add Notes, Comments or Ask Questions

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK